Protara Therapeutics logo

Protara TherapeuticsNASDAQ: TARA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

22 October 2014

Next earnings report:

01 November 2024

Last dividends:

N/A

Next dividends:

N/A
$41.26 M
-52%vs. 3y high
33%vs. sector
-vs. 3y high
-vs. sector
-65%vs. 3y high
26%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Thu, 24 Oct 2024 20:24:54 GMT
$2.00+$0.12(+6.38%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

TARA Latest News

Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
globenewswire.com09 September 2024 Sentiment: POSITIVE

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the results of THRIVE-1, a prospective, observational study evaluating the prevalence of choline deficiency and liver injury in patients dependent on parenteral support (PS). Results from the study were featured during a poster session at the 46th European Society for Clinical Nutrition and Metabolism Congress (ESPEN), from September 7, 2024, to September 10, 2024, in Milan.

Here's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Now
Zacks Investment Research12 April 2024 Sentiment: POSITIVE

Protara Therapeutics (TARA) has shown a hammer chart pattern, suggesting that the stock has found support after a recent decline. This, along with an increase in earnings estimate revisions, may indicate a potential turnaround for the stock in the near future.

What type of business is Protara Therapeutics?

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

What sector is Protara Therapeutics in?

Protara Therapeutics is in the Healthcare sector

What industry is Protara Therapeutics in?

Protara Therapeutics is in the Biotechnology industry

What country is Protara Therapeutics from?

Protara Therapeutics is headquartered in United States

When did Protara Therapeutics go public?

Protara Therapeutics initial public offering (IPO) was on 22 October 2014

What is Protara Therapeutics website?

https://www.protaratx.com

Is Protara Therapeutics in the S&P 500?

No, Protara Therapeutics is not included in the S&P 500 index

Is Protara Therapeutics in the NASDAQ 100?

No, Protara Therapeutics is not included in the NASDAQ 100 index

Is Protara Therapeutics in the Dow Jones?

No, Protara Therapeutics is not included in the Dow Jones index

When was Protara Therapeutics the previous earnings report?

No data

When does Protara Therapeutics earnings report?

The next expected earnings date for Protara Therapeutics is 01 November 2024